Journal For Immunotherapy Of Cancer . September 2022 - Volume 10 - 9 .
NEMVALEUKIN Inhibió Significativamente el Crecimiento del Tumor SCLC Murino y Prolongó la Supervivencia, Que Mejoró Aún Más con la Adición de Quimioterapia .
NEMVALEUKIN Alfa, A Novel Engineered IL-2 Fusión Protein, Drives Antitumor Immunity And Inhibits Tumor Growth In SMALL CELL LUNG CÁNCER .
NEMVALEUKIN, a Novel Cytokine-Based Immunotherapy, Significantly Inhibited Murine SCLC Tumor Growth rowth and Prolonged Survival, Which Was Further Enhanced by the Addition of Chemotherapy .
NEMVALEUKIN Alone, and in Combination With Chemotherapy, Drove a Strong Antitumor Immune Program Elicited by Cytotoxic Immune Cells .
Our Findings Support the Evaluation of NEMVALEUKIN Alone or in Combination With Chemotherapy in Clínical Trials For The Treatment of SCLC . ...